Abstract

The present invention provides an adaptable thin lens for correcting visual aberrations, including a plurality of design elements organized in at least one optical zone, wherein the design elements are selected from a concave design, a convex design, a piano design, a Fresnel-like design, a free-form prism design, and combinations thereof, the adaptable thin lens being capable of being placed into any desired frame of glasses or sunglasses, and to be attached to or printed on an existing lens, while providing adequate correction of visual aberrations.

IPC Classes  ?

• G02C 7/02 - LensesLens systems
• G02C 7/08 - Auxiliary lensesArrangements for varying focal length

Abstract

This disclosure describes a Machine Learning (ML) framework, including graph convolution neural networks (GCN) for identifying gene expression signatures related to cancer driver events. The model is trained to identify the TP53 mutational state of cancer samples from gene expression, utilizing comprehensive curated graph structures of gene interactions. A quantitative score is generated to rank the severity of a driver event in each sample. Very high AUG results on unseen data across several tumor types are achieved with this method. There is a strong correlation with protein function. The Signatures in Transcriptome Associated with Mutated Protein (STAMP) model can also predict driver events in many combinations of important cancer genes/pathways and several tumor types, based on well-established annotations from the literature. The STAMP model therefore can identify and quantify driver events, which may lead the way to improved targeted therapy selection and prioritization in cancer patients.

Abstract

The present disclosure relates in general to the field of genetic engineering of immune cells, specifically to mucosal-associated invariant T (MAIT) cells genetically engineered to express an exogeneous T cell receptor (TCR) and uses thereof. More specifically, the invention in embodiments thereof relates to cell compositions adapted for adoptive transfer cell therapy (ACT) providing for improved therapeutic modalities.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

This invention relates to a method and system for non-invasively monitoring central venous pressure, using a set of microneedles and micro-electromechanical systems, e.g., in heart failure. Herein, the microneedle-based sensor attaches to the skin at the neck of a subject to monitor central venous pressure, as it is a direct representative of filling pressures causing skin sub-surface strain.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/0215 - Measuring pressure in heart or blood vessels by means inserted into the body
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• A61B 17/00 - Surgical instruments, devices or methods
• A61B 5/021 - Measuring pressure in heart or blood vessels
• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow

Abstract

An apparatus (100) for measuring an intraocular pressure of an eye (101) includes a deformation capsule (106) containing a fluid (109) and configured to deform as the deformation capsule is pressed against an eyelid (124) of the eye while the eye is closed, thereby causing a change in a pressure of the fluid. The apparatus further includes at least one pressure sensor (110) configured to connect to the deformation capsule and to output a pressure-sensor signal indicative of the change in the pressure of the fluid, and a force sensor (102) configured to connect to the deformation capsule and to output a force-sensor signal indicative of a force with which the deformation capsule is pressed against the eyelid. The intraocular pressure is derivable from the change in the pressure of the fluid and the force. Other embodiments are also described.

IPC Classes  ?

• A61B 3/16 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for measuring intraocular pressure, e.g. tonometers
• A61B 3/02 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient

Abstract

Provided herein are isolated peptides capable of affecting neuroligin-4 (NLGn4)-neurexin 1β (Nrx1β) protein-protein interaction and interfering with NLGn4X/Nrx1β axis between Hepatic Stellate Cells (HSCs) and Natural killer (NK). Further provided are compositions including such peptides and uses thereof for treating and/or attenuating liver-related conditions and various types of cancer.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 35/00 - Antineoplastic agents
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

Compounds represented by general Formulae I to IV as described herein are disclosed. Further disclosed are composition utilizing the herein disclosed compounds and using the same for the treatment of glycogen storage disorders.

IPC Classes  ?

• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 487/08 - Bridged systems

Abstract

Methods of inhibiting reactive oxygen species production by neutrophils or treating neutrophil-mediated inflammation in a subject by contacting the neutrophils with or administering an agent selected from a cyclin dependent kinase 4 (CDK4) inhibitor, a cyclin dependent kinase 6 (CDK6) inhibitor, an epidermal growth factor receptor (EGFR) inhibitor, a proto-oncogene tyrosine-protein kinase Src (SRC) inhibitor and a sodium (Na) channel blocker are provided. Pharmaceutical compositions comprising a nanoparticle, the agent and a neutrophil targeting peptide are also provided.

IPC Classes  ?

• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention is directed to the field of immunotherapy. Specifically, the invention provides improved cell compositions and methods for adoptive cell therapy, useful in the treatment of cancer. More specifically, embodiments of the invention employ the use of cell compositions comprising a high proportion of activated cytotoxic CD8+ cells and in particular CD8+NKG2D+granzyme-B+ cells characterized by enhanced cytotoxicity, to processes for their preparation from peripheral blood mononuclear cells (PBMC), and to their use in cancer management.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 14/54 - Interleukins [IL]
• C07K 14/55 - IL-2
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin

Abstract

A support device for a pulsating organ is comprised of a structure formed at least partially of one or more polymers. The structure is configured to transition, in response to a stimulus, between a placement shape, in which the support device is dimensioned larger than the dimensions of the organ, and a treatment shape, in which the support device provides therapeutic support to the organ; wherein the treatment shape is smaller than the placement shape. Preferably, the polymers are shape memory polymers. The support device may be manufactured in an initial shape in which the one or more shape memory polymers are in their permanent shapes, and the placement shape is larger than or equivalent to the initial shape. Optionally, the stimulus is application of an aqueous medium. Embodiments of support devices may be used for treatment of heart failure with reduced ejection fraction and with preserved ejection fraction.

IPC Classes  ?

• A61L 27/16 - Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/50 - Materials characterised by their function or physical properties
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances

Abstract

The present disclosure provides methods of using a compound effective in reducing GPI- anchored CD59 expression or activity in the liver for treatment of a liver disease or condition. Examples of compounds useful for the methods include oligonucleotides, for example but not limited to antisense oligonucleotides, interfering RNA compounds (RNAi), siRNA, miRNA, or guide RNA.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 5/50 - Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Abstract

The present disclosure relates to manipulation of splicing of the Fas (tumor necrosis factor (TNF) receptor superfamily, member 6) gene in non-naive cell of the T lineage for enhanced skipping of exon 6. The manipulated non-naive cells predominantly express a soluble form of Fas (sFas) and display reduced expression of the membranal Fas (mFas), increased cytokine secretion, increased expression of activation markers, increased cell survival, increased cytotoxicity, and/or reduced expression of exhaustion markers. The present disclosure further provides specific splicing modulatory agents comprising gene editing systems and/or splice switching antisense oligonucleotide (SSO), methods and therapeutic uses thereof.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents

Abstract

Provided herein are rapidly dissolving microneedle arrays comprising nanoparticles disposed distally in said microneedles, methods of manufacturing same, and uses of same in treating a disease or disorder in a subject in need thereof. The microneedles dissolve rapidly upon administration depositing the nanoparticles comprising pharmaceutically active agents into the viable epidermis layer of the skin.

IPC Classes  ?

• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin

Abstract

Apparatus is provided including an intradural catheter (22) configured to be passed into a spinal canal of a subject, and to be advanced toward a compressed nerve. An inflatable element (40) disposed in the intradural catheter and configured to be inflated from a collapsed state to an inflated state, such that when in the inflated state the inflatable element (40) is shaped to define an outer wall (42), an inner wall (44) and a cavity (46) at least partially surrounded by the inner wall. The inflatable element is inflated, through the intradural catheter, around the nerve such that (a) the nerve is disposed in the cavity surrounded by the inner wall of the inflatable element, and (b) the outer wall of the inflatable element is inflated outwardly to apply pressure in a direction that is away from the nerve. Other applications are also described.

IPC Classes  ?

• A61B 17/00 - Surgical instruments, devices or methods
• A61F 2/30 - Joints
• A61B 17/88 - Methods or means for implanting or extracting internal fixation devices
• A61M 25/10 - Balloon catheters
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• A61F 2/82 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
• A61B 1/313 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for introducing through surgical openings, e.g. laparoscopes
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 1/005 - Flexible endoscopes
• A61B 17/34 - TrocarsPuncturing needles
• A61M 25/00 - CathetersHollow probes
• A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

Provided herein are compositions and methods for introducing a genetic change in the genome of a cell with an exogenous DNA template-free Cas-based genome editing system comprising: (i) identifying a target genomic sequence of the genome comprising 88% or higher homology with one or more paralogs or pseudogenes that differ by one or more nucleotides; wherein the homologous region in the one or more paralogs or pseudogenes having a desired nucleotide sequence for transfer to the target genomic sequence after a double-strand break (DSB) by Cas-based genome editing; (ii) introducing into the cell a variant-specific sgRNA to cause a unidirectional transfer of genomic DNA from the homologous DNA sequences to the target genomic sequence, and (iii) contacting the genome of the cell with the variant-specific sgRNA and a Cas-based genome editing system, thereby introducing the genetic conversion without the exogenous DNA template.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 9/22 - Ribonucleases
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Abstract

Methods of diagnosing graft versus host disease (GVHD) comprising quantifying cfDNA or employing a machine learning model are provided. Methods comprising training a machine learning model are also provided.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Disclosed herein is a polypeptide including a pharmaceutical composition for use in prevention or treatment of a disease or a disorder associated with lysosomal storage and an autophagy-misregulation associated disease. Further provided are agents that bind a region of an N-terminal domain of a lysosomal-associated membrane protein 1 (LAMP-1), and methods for treating or preventing development of a disease or a disorder associated with lysosomal storage, polyglucosan accumulation or abnormal glycogen accumulation and autophagy-misregulation in a subject in need thereof.

IPC Classes  ?

• A61K 31/4436 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

The present disclosure relates to small molecule compound (SMC) modulators, compositions comprising the SMC modulators, uses thereof and methods for their use in modulating activity of CCR1 in a Muller cell and treating retinal disease.

IPC Classes  ?

• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61P 27/02 - Ophthalmic agents
• A61P 27/06 - Antiglaucoma agents or miotics

Abstract

Disclosed herein are devices/kits and methods for reducing, treating, preventing or eliminating post-operative adhesions in an intervention/target site within a body of a subject. The method comprises the steps of: introducing an applicator, configured for applying an anti-adhesive composition, into an intervention/target site within a body of a subject; applying the anti-adhesive composition onto the intervention/target site; and extracting the applicator from the body of the subject, wherein the method is performed during or following an interventional procedure.

IPC Classes  ?

• A61L 31/04 - Macromolecular materials
• A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
• A61K 31/734 - Alginic acid
• A61K 33/14 - Alkali metal chloridesAlkaline earth metal chlorides

Abstract

A computer-implemented method comprising: receiving, as input, a plurality of DNA sequencing samples corresponding to a cohort of subjects having various tumor types; annotating each of the DNA sequencing samples with annotations indicating (a) a tumor type associated with the DNA sequencing sample, (b) one or more mutations represented in the DNA sequencing sample, and (c) at least one dominant mutational signature associated with the DNA sequencing sample; at a training stage, training a machine learning model on a training dataset comprising: (i) the DNA sequencing samples, and (ii) labels indicating the annotations; and at an inference stage, applying the trained machine learning model to a target DNA sequencing sample from a target subject, to predict a dominant mutational signature associated with the target DNA sequencing sample.

IPC Classes  ?

• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G16B 40/20 - Supervised data analysis
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

This invention provides in some aspects, combinations, compositions and kits comprising a psychedelic drug and an NMD A receptor agonist and applications and uses of same for treating, reducing the incidence of, reducing the severity of or improving a pathology of a subject with a neurologic disease or disorder, a neurocognitive disease or disorder, or a motor disease or disorder, or for enhancing neuroplasticity in a subject with a neurologic disease or disorder, a neurocognitive disease or disorder, or a motor disease or disorder making use of the combinations, compositions and kits of this invention.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A film and a method for use thereof such as for the administration of a biologically active agent or for therapy are provided. Specifically, a film, composed of a biodegradable material having a mucoadhesive surface comprising a plurality of mushroom-type structures is provided.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention relates to engineered T cell receptors (TCRs) directed to cancer testis antigen New York Esophageal Squamous Cell Carcinoma- 1 (NY-ESO-1), useful in the treatment of cancer. In particular, provided are isolated TCR polypeptides, as well as corresponding nucleic acid molecules and cell compositions, characterized by improved properties that are particularly adapted to cancer immunotherapy.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C12N 15/86 - Viral vectors

Abstract

The present disclosure relates to combination the combination, pharmaceutical compositions and kits comprising at least two small molecule inhibitors (SMIs) of respectively at least two proteins of different signaling pathways of retinal disease and methods for treating a retinal disease.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 27/02 - Ophthalmic agents
• A61P 35/00 - Antineoplastic agents
• A61K 31/402 - 1-aryl-substituted, e.g. piretanide
• A61K 31/4164 - 1,3-Diazoles
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
• C07D 207/273 - 2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

The present invention is directed vectors comprising a FCBR1-F0.4 promotor or an IRBP-GRK1 promotor and a nucleic acid sequence encoding a ciliary protein, or fragment or variant thereof. In particular, the invention relates to a method of treatment and prevention of retinal ciliopathies, such as retinitis pigmentosa 28.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

Abstract

A method comprising: receiving a set of eye images of a cohort of subjects, and a plurality of datapoints with respect to each of the subjects in the cohort, wherein at least some of the subjects in the cohort of are associated with a diagnosis of a specific eye condition; extracting, with respect to each of the subjects, a set of features representing the images and the datapoints associated with the subject; at a training stage, training a machine learning model on a training dataset comprising: (i) all of the sets of features, and (ii) labels indicating a diagnosis of an eye condition associated with each of the subjects; and at an inference stage, applying the trained machine learning model to a target dataset comprising one or more images and associated datapoints with respect to a target subject, to output a diagnosis of an eye condition in the target subject.

IPC Classes  ?

• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
• A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
• A61B 3/14 - Arrangements specially adapted for eye photography

Abstract

The techniques described herein disclose a method or a system for analyzing genomic data, calculating a predictor and making a quantitative assessment of a biological effect based on the predictor. A biological effect such as the pathogenicity of a cancer a risk that a subject may develop a particular cancer may be determined based on the predictor. The predictor may comprise the observed number of occurrences of a gene variant divided by the expected number of occurrences of the gene variant. The prediction of a drug treatment may comprise prioritization of gene variants according to a selective variant effect and determining which drug treatment to prioritize. The predictions may further comprise using genomic coordinates for each gene variant and nucleotide alterations from various databases, but filtering out duplicate samples from the same subject.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G16B 50/00 - ICT programming tools or database systems specially adapted for bioinformatics
• G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
• G16H 70/60 - ICT specially adapted for the handling or processing of medical references relating to pathologies

Abstract

An apparatus includes an intraosseous appliance formed to have hollow channels open to a proximal extradermal surface of the appliance. Optical emitters and detectors reside within channels of the intraosseous appliance having distal openings in a distal base of the intraosseous appliance, in a lateral surface of the intraosseous appliance, and in an extradermal surface of the intraosseous appliance, so as to establish optical paths between the optical emitters and detectors and, respectively, the dura, bone wall of a bun hole and skin of the subject. Intracerebral and extracerebral electrodes reside within respective channels of the intraosseous appliance having distal openings in the distal base of the intraosseous appliance and in the extradermal surface of the intraosseous appliance, respectively.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

Disclosed herein are methods and systems for identifying a position of a plurality of electrodes in an EEG electrode array embedded to an EEG electrode array carrier when the EEG electrode array carrier is worn on a head of a subject. A first system is an optical system containing a stereo camera pair which captures at least one image of the head of the subject wearing the EEG electrode array carrier. A second system is an electrical system which constructs a 3D electrical model of the EEG electrode array and an electrical model of a couplant spreading of the couplant which couples the electrodes to the head of the subject. The two systems may be integrated to one electro-optical system for identifying a position of electrodes in an EEG electrode array on a head of a subject.

IPC Classes  ?

• A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06T 7/30 - Determination of transform parameters for the alignment of images, i.e. image registration

Abstract

Disclosed are methods of treatment, compositions and kits comprising endocannabinoid receptor (ECR) antagonist and an mTOR inhibitor for treating neoplasm in a subject in need thereof, and reducing drug resistance to standard treatment.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61P 35/00 - Antineoplastic agents

Abstract

In vitro populations of enhanced mesenchymal stem cells (eMSCs) are provided. Pharmaceutical compositions comprising the eMSC populations as well as methods of culturing MSCs to produce the eMSC populations and use of the populations and compositions are also provided.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Described herein are methods for differentiating human pluripotent stem cells into populations of retinal cells comprising photoreceptor neural cells (PNCs) in dynamic culture. Also provided are cells and cellular compositions obtained by such methods, and uses of such cells in a suspension or imbedded in a scaffold that can be administered to a subject suffering from a retinal disease or disorder.

IPC Classes  ?

• C12N 5/0793 - Neurons
• C12N 5/079 - Neural cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention provides peptides derived from the cytoplasmic region of protease-activated receptors 4 (PAR4) as well as analogs and cyclic analogs, such as backbone cyclic analogs, of these peptides. Pharmaceutical compositions comprising said peptides, analog, cyclic analogs and well as conjugates thereof are provided as well. The peptides, analogs and conjugates of the present invention and pharmaceutical composition comprising thereof have several uses including treating cancer such as cancer expressing PAR proteins such as cancer expressing ErbB protein and triple negative cancer. and inhibiting interactions between PARs and protein comprising PH-domain.

IPC Classes  ?

• C07K 7/64 - Cyclic peptides containing only normal peptide links
• A61P 35/00 - Antineoplastic agents

Abstract

Disclosed herein are flexible microneedle arrays with improved characteristics, such as durability and high drug loading. Further disclosed methods of manufacturing the microneedle arrays, and uses thereof in treatment of a disease or a condition in a patient in need thereof.

IPC Classes  ?

• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Abstract

NNN-diacetic acid, formulated as either liquid compositions that upon warming to body temperature solidify into a viscous gel; or solid dosage forms, which are useful as dental compositions for removing microbial biofilm, or inhibiting or disrupting formation thereof.

IPC Classes  ?

• A61Q 11/02 - Preparations for deodorising, bleaching or disinfecting dentures
• A61K 6/52 - CleaningDisinfecting
• A61K 6/60 - Preparations for dentistry comprising organic or organo-metallic additives
• A61K 6/74 - Fillers comprising phosphorus-containing compounds

Abstract

A method is described for determining a disease progression and survival prognosis, at a succession of prediction times, for patients suffering from amyotrophic lateral sclerosis (ALS). The method comprises a step of defining a set of variables associated with the onset and progression of amyotrophic lateral sclerosis, comprising a first group of variables associated with the onset of amyotrophic lateral sclerosis (comprising at least the variables “patient sex”, “disease onset age”, “disease onset site”), a second group of dynamic time variables (comprising at least the variable “time elapsed since disease onset”), a third group of dynamic functional variables (comprising at least one of the variables breathing, swallowing, communicating, walking/self-care or at least one variable of a functional progression and/or severity scale of amyotrophic lateral sclerosis), and further at least one variable associated with survival. The method further provides for encoding by means of a Dynamic Bayesian Network, using at least one trained algorithm, a plurality of probabilistic conditional dependence relationships, in which each relationship is a probabilistic conditional dependence relationship between two of the aforesaid variables. The aforesaid prediction times are defined so that each prediction time belongs to a respective time interval in which the conditional dependence relationships between the variables are stationary. The method further involves describing the Dynamic Bayesian Network, using at least one trained algorithm, by means of a corresponding graph, comprising said variables as nodes and comprising topological connections oriented between nodes corresponding to variables among which a probabilistic conditional dependence is identified. In the graph, given a node, the connections entering it show a conditional probability of the value assumed by the variable associated with such node, in a given prediction time, depending on the values assumed, in a prior prediction time, from the variables associated with the nodes from which such connections originate. The method further comprises the steps of entering, for each of the defined variables, data acquired at a given acquisition time relating to the situation of a specific patient; and calculating, by electronic processing and/or calculating means, on the basis of the Dynamic Bayesian Network and the graph, and starting from the aforesaid acquired data, the values of each of the defined variables, at one or more prediction times following the acquisition time. Finally, the method involves obtaining, in a given prediction time, disease progression prognosis results on the basis of the values of one or more of the variables of the third group calculated in such prediction time; and the survival prognosis results on the basis of the value of at least one variable associated with survival, calculated at such prediction time.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G06N 7/01 - Probabilistic graphical models, e.g. probabilistic networks

Abstract

Provided herein are isolated peptides capable of affecting neuroligin-4 (NLGn4)-neurexin ip (Nrxip) protein-protein interaction and interfering with NLGn4X/Nrxip axis between Hepatic Stellate Cells (HSCs) and Natural killer (NK). Further provided are compositions including such peptides and uses thereof for treating and/or attenuating liver-related conditions and various types of cancer.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to an heparanase-binding and heparanase-neutralizing monoclonal antibody (IgG-1 mAb A54), including its epitope (HBD-II) and mode of interaction with heparanase, pharmaceutical composition comprising same, and uses thereof e.g. for inhibiting or treating a disease or disorder associated with heparanase activity, including but not limited to cancer, inflammation, viral infection, diabetes and related complications. The present invention further provides combinatorial cancer therapies, comprising the heparanase-neutralizing mAb and an additional anti-cancer treatment such as chemotherapy or radiation.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61P 35/00 - Antineoplastic agents
• A61K 31/69 - Boron compounds
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid

Abstract

The present disclosure provides chimeric antigen receptor (CAR) molecule specific for B cell maturation antigen (BCMA), compositions and methods for treating immune-related disorders, specifically, plasma cell pathologies such as multiple myeloma (MM).

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 9/22 - Ribonucleases
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

A method of detecting death of a cell type or tissue in a subject is disclosed. The method comprises determining whether cell-free DNA comprised in a fluid sample of the subject is derived from the cell type or tissue, wherein the determining is effected by ascertaining the methylation status of at least four methylation sites on a continuous sequence of the cell-free DNA, the sequence comprising no more than 300 nucleotides, wherein a methylation status of each of the at least four methylation sites on the continuous sequence of the DNA characteristic of the cell type or tissue is indicative of death of the cell type or tissue. Kits for detecting cell death are also disclosed.

IPC Classes  ?

• C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The invention relates to isolated antibodies or antigen-binding fragments thereof that binds to the human Lymphocyte antigen 6 family member K (LY6K) and their use as antibody-drug conjugate, in screening for LY6K-positive malignant cells and for the treatment of LY6K-positive cancer. Three exemplified murine and humanized antibodies have complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• G01N 33/577 - ImmunoassayBiospecific binding assayMaterials therefor involving monoclonal antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure relates generally to compositions and methods for determining cell type based on a methylation profile of associated DNA. For cell free DNA, such determination can be used to identify disease or conditions relating to the cell type. For tumor cells, such determination is useful for identifying their primary origin.

IPC Classes  ?

• C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes

Abstract

The present disclosure relates generally to compositions and methods for determining cell type based on a methylation profile of associated DNA. For cell free DNA, such determination can be used to identify disease or conditions relating to the cell type. For tumor cells, such determination is useful for identifying their primary origin.

IPC Classes  ?

• C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present disclosure relates generally to compositions and methods for determining cell type based on a methylation profile of associated DNA. For cell free DNA, such determination can be used to identify disease or conditions relating to the cell type. For tumor cells, such determination is useful for identifying their primary origin.

IPC Classes  ?

• C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes

Abstract

A computer-implemented method comprising: receiving genetic information with respect to a plurality of known variants of a gene of interest; calculating, based on the received genetic information, for each of the variants, a set of features representing a functional estimation or a loss of function (LOF) associated with the variant; at a training stage, training a machine learning model on a training dataset comprising: (i) all of the sets of features, and (ii) labels indicating a pathogenicity associated with each of the variants; and at an inference stage, applying the trained machine learning model to an unseen target variant of the gene of interest, to predict a pathogenicity of the unseen target variant of the gene of interest.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16B 40/20 - Supervised data analysis
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection

Abstract

The invention generally concerns peripherally restricted CB1 antagonists for treatment of LUTS.

IPC Classes  ?

• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 13/00 - Drugs for disorders of the urinary system
• A61P 13/10 - Drugs for disorders of the urinary system of the bladder

Abstract

The present invention relates to a device for repair of a region within an ear via a natural orifice, the device comprising a body. The body comprises a first port for visibly identifying the region to be sealed, the region being inside the ear; and a second port through which a seal can be introduced into the ear through the device. The region comprises a perforation of a tympanic membrane of the ear and the device is a speculum. The present invention also relates to method for repairing a perforation in a tympanic membrane using the same device.

IPC Classes  ?

• A61F 11/20 - Ear surgery
• A61B 1/227 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for ears, i.e. otoscopes
• A61F 2/18 - Internal ear or nose parts, e.g. ear-drums

Abstract

The present invention provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising use of artemisone in combination with at least one antiviral compound selected from maribavir, cidofovir, brincidofovir, valganciclovir, and letermovir, and the combination provides a synergistic anti-viral effect. The invention also provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising the use of artemisone in combination with ganciclovir, wherein the molar ratio between artemisone and ganciclovir is about 1:100 to 100:1, and the combination provides a synergistic anti-viral effect. Pharmaceutical compositions comprising artemisone and at least one of said antiviral compounds are provided as well.

IPC Classes  ?

• A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
• A61P 31/12 - Antivirals
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom

Abstract

Provided herein are methods, compositions of matter, and devices for treating diseases and illnesses of the eye, including retinal conditions such as macular degeneration.

IPC Classes  ?

• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 27/02 - Ophthalmic agents
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Compounds represented by general Formulae I to IV as described herein are disclosed. Further disclosed are composition utilizing the herein disclosed compounds and using the same for the treatment of glycogen storage disorders.

IPC Classes  ?

• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 487/08 - Bridged systems

Abstract

The present invention provides biomarkers allowing the diagnosis of symptomatic congenital cytomegalovirus (CMV) infection and in particular to differentiate between symptomatic and asymptomatic infected fetuses, methods of diagnosis of CMV using said biomarkers, diagnostic kits comprising thereof, and use of the kits and methods of diagnosing fetuses infected with a symptomatic congenital cytomegalovirus (CMV).

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The invention relates to cancer management, specifically to therapeutic combinations and methods for immunotherapy of tumors and malignancies. More specifically, embodiments of the invention provide compositions, methods, pharmaceutical packages and combined preparations employing the use of a SLAMF6-mediated T cell activator in combination with a LAG3 inhibitor.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to nucleic acid agents modulating the expression of SLAMF6 isoforms, compositions comprising same and methods for their use in immunomodulation. Specifically, provided are splice-switching oligonucleotides and constructs useful in cancer immunotherapy.

IPC Classes  ?

• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes

Abstract

The present invention relates to the use of pomegranate oil and fractions thereof for preventing and treating neurodegenarative diseases. Particularly, the present invention relates to emulsions of the pomegranate oil or fractions thereof for the prevention and treatment of brain diseases, including Creutzfeldt-Jacob disease (CJD) and multiple sclerosis (MS).

IPC Classes  ?

• A61K 9/107 - Emulsions
• A23L 33/115 - Fatty acids or derivatives thereofFats or oils
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Abstract

Disclosed herein is a polypeptide including a pharmaceutical composition for use in prevention or treatment of a disease or a disorder associated with lysosomal storage and an autophagy-misregulation associated disease. Further provided are agents that bind a region of an N-terminal domain of a lysosomal-associated membrane protein 1 (LAMP-1), and methods for treating or preventing development of a disease or a disorder associated with lysosomal storage, polyglucosan accumulation or abnormal glycogen accumulation and autophagy-misregulation in a subject in need thereof.

IPC Classes  ?

• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Disclosed herein is a polypeptide including a pharmaceutical composition for use in prevention or treatment of a disease or a disorder associated with lysosomal storage and an autophagy-misregulation associated disease. Further provided are agents that bind a region of an N-terminal domain of a lysosomal-associated membrane protein 1 (LAMP-1), and methods for treating or preventing development of a disease or a disorder associated with lysosomal storage, polyglucosan accumulation or abnormal glycogen accumulation and autophagy-misregulation in a subject in need thereof.

IPC Classes  ?

• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present disclosure provides endoscopic retrograde cholangiopancreatography (ERCP) catheter systems having multiple ports and sensors configured to determine the location of the catheter's and/or guidewire's distal end as well as optional one or more magnetic bending aids, configured to aim a guidewire to the desired duct location. Further provided is a guidewire having a magnetic end and optional sensing elements. Also provided are methods of using the catheters and/or guidewires in ERCP procedures.

IPC Classes  ?

• A61M 25/00 - CathetersHollow probes
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 5/0538 - Measuring electrical impedance or conductance of a portion of the body invasively, e.g. using a catheter
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
• A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
• A61M 25/06 - Body-piercing guide needles or the like

Abstract

A method of generating human mature oligodendrocytes is disclosed. The method comprises contacting a cell population which comprises human pre-oligodendrocytes with an inhibitor of the MAPK/ERK pathway under conditions that allow the pre-oligodendrocytes to differentiate into mature oligodendrocytes. Use of the MAPK/ERK pathway inhibitor for treating diseases is also disclosed.

IPC Classes  ?

• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• C12N 5/079 - Neural cells
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates to anti-microbially active micro and nanoparticles, compositions comprising same, and use thereof for inhibiting bacterial growth and biofilm formation on surfaces or devices, e.g., dental surfaces or devices. The present invention further discloses methods of making such anti-microbially active micro or nanoparticles.

IPC Classes  ?

• A01N 33/12 - Quaternary ammonium compounds
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 6/80 - Preparations for artificial teeth, for filling teeth or for capping teeth
• A01N 25/12 - Powders or granules
• A61K 8/25 - SiliconCompounds thereof
• A61K 8/41 - Amines
• C08K 9/04 - Ingredients treated with organic substances

Abstract

A culture of human pluripotent stem cells (hPSCs) is disclosed. In the culture, more than 50% of the hPSCs are formative hPSCs and are capable of renewing. Uses thereof are also disclosed.

IPC Classes  ?

• C12N 5/074 - Adult stem cells
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues

Abstract

A method of treating bacterial vaginosis in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a composition which comprises between three and twenty species of bacteria or a secretion thereof, wherein at least 70% of the bacteria of the composition are of the species Lactobacillus crispatus, thereby treating the bacterial vaginosis.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 31/04 - Antibacterial agents

Abstract

A film and a method for use thereof such as for the administration of a biologically active agent or for therapy are provided. Specifically, a film, composed of a biodegradable material having a mucoadhesive surface comprising a plurality of mushroom-type structures is provided.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
• A61P 31/10 - Antimycotics
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

In vitro populations of enhanced mesenchymal stem cells (eMSCs) are provided. Pharmaceutical compositions comprising the eMSC populations as well as methods of culturing MSCs to produce the eMSC populations and use of the populations and compositions are also provided.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells

Abstract

Compounds, compositions and methods for modulating retinoic acid receptor-like orphan receptors (ROR) so as to increase FGF21 levels, and treating and preventing disorders associated with FGF21, such as pancreatitis, sarcopenia, stroke, and traumatic brain injury, and to increase miR-122 levels, and treating and preventing disorders such as glioblastoma.

IPC Classes  ?

• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 3/06 - Antihyperlipidemics
• A61P 35/00 - Antineoplastic agents

Abstract

Compounds, compositions and methods for modulating retinoic acid receptor-like orphan receptors (ROR) so as to increase FGF21 levels, and treating and preventing disorders associated with FGF21, such as pancreatitis, sarcopenia, stroke, and traumatic brain injury, and to increase miR-122 levels, and treating and preventing disorders such as glioblastoma.

IPC Classes  ?

• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Abstract

The present invention provides peptides derived from the cytoplasmic region of protease-activated receptors 4 (PAR4) as well as analogs and cyclic analogs, such as backbone cyclic analogs, of these peptides. Pharmaceutical compositions comprising said peptides, analog, cyclic analogs and well as conjugates thereof are provides as well. The peptides, analogs and conjugates of the present invention and pharmaceutical composition comprising thereof have several uses including treating cancer and inhibiting interactions between PARs and protein comprising PH-domain.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61P 35/00 - Antineoplastic agents

Abstract

A method of generating retinal pigment epithelial (RPE) cells is disclosed. The method comprises: (a) culturing human pluripotent stem cells in a human feeder cell-conditioned medium to obtain a cultured population of human pluripotent stem cells; (b) culturing said cultured population of human pluripotent stem cells in a medium comprising a differentiating agent to obtain differentiating cells; and (c) culturing said differentiating cells in a medium comprising one or more members of the TGFβ superfamily.

IPC Classes  ?

• C12N 5/079 - Neural cells
• A61P 27/02 - Ophthalmic agents
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue

Abstract

A method of detecting death of a cell type or tissue in a subject is disclosed. The method comprises determining whether cell-free DNA comprised in a fluid sample of the subject is derived from the cell type or tissue, wherein the determining is effected by ascertaining the methylation status of at least four methylation sites on a continuous sequence of the cell-free DNA, the sequence comprising no more than 300 nucleotides, wherein a methylation status of each of the at least four methylation sites on the continuous sequence of the DNA characteristic of the cell type or tissue is indicative of death of the cell type or tissue. Kits for detecting cell death are also disclosed.

IPC Classes  ?

• C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Provided are methods and kits for early determination of disease outcome and prognosis of Multiple Sclerosis (MS) patients and for adjustment of suitable treatment.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention is directed to a nanoparticle including: a core of a metal chelating polymer, wherein the core is coated with at least two layers of magnetic metal oxide, which are further coated with a protein layer, and at least one active agent bound within or to the nanoparticle, methods for directing or targeting the nanoparticle via a magnetic field to a target tissue, and a computer program for efficiently generating the proper magnetic field for driving the nanoparticle to or into a given target tissue.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 9/51 - Nanocapsules
• A61P 35/00 - Antineoplastic agents

Abstract

A method is described for determining a disease progression and survival prognosis, at a succession of prediction times, for patients suffering from amyotrophic lateral sclerosis (ALS). The method comprises a step of defining a set of variables associated with the onset and progression of amyotrophic lateral sclerosis, comprising a first group of variables associated with the onset of amyotrophic lateral sclerosis (comprising at least the variables "patient sex", "disease onset age", "disease onset site"), a second group of dynamic time variables (comprising at least the variable "time elapsed since disease onset"), a third group of dynamic functional variables (comprising at least one of the variables breathing, swallowing, communicating, walking/self-care or at least one variable of a functional progression and/or severity scale of amyotrophic lateral sclerosis), and further at least one variable associated with survival. The method further provides for encoding by means of a Dynamic Bayesian Network, using at least one trained algorithm, a plurality of probabilistic conditional dependence relationships, in which each relationship is a probabilistic conditional dependence relationship between two of the aforesaid variables. The aforesaid prediction times are defined so that each prediction time belongs to a respective time interval in which the conditional dependence relationships between the variables are stationary. The method further involves describing the Dynamic Bayesian Network, using at least one trained algorithm, by means of a corresponding graph, comprising said variables as nodes and comprising topological connections oriented between nodes corresponding to variables among which a probabilistic conditional dependence is identified. In the graph, given a node, the connections entering it show a conditional probability of the value assumed by the variable associated with such node, in a given prediction time, depending on the values assumed, in a prior prediction time, from the variables associated with the nodes from which such connections originate. The method further comprises the steps of entering, for each of the defined variables, data acquired at a given acquisition time relating to the situation of a specific patient; and calculating, by electronic processing and/or calculating means, on the basis of the Dynamic Bayesian Network and the graph, and starting from the aforesaid acquired data, the values of each of the defined variables, at one or more prediction times following the acquisition time. Finally, the method involves obtaining, in a given prediction time, disease progression prognosis results on the basis of the values of one or more of the variables of the third group calculated in such prediction time; and the survival prognosis results on the basis of the value of at least one variable associated with survival, calculated at such prediction time.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

The present invention relates to an heparanase-binding and heparanase-neutralizing monoclonal antibody (IgG-1 mAb A54), including its epitope (HBD-II) and mode of interaction with heparanase, pharmaceutical composition comprising same, and uses thereof e.g. for inhibiting or treating a disease or disorder associated with heparanase activity, including but not limited to cancer, inflammation, viral infection, diabetes and related complications. The present invention further provides combinatorial cancer therapies, comprising the heparanase-neutralizing mAb and an additional anti-cancer treatment such as chemotherapy or radiation.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C12N 15/13 - Immunoglobulins

Abstract

Method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction; and compositions including the agent.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to an heparanase-binding and heparanase-neutralizing monoclonal antibody (IgG-1 mAb A54), including its epitope (HBD-II) and mode of interaction with heparanase, pharmaceutical composition comprising same, and uses thereof e.g. for inhibiting or treating a disease or disorder associated with heparanase activity, including but not limited to cancer, inflammation, viral infection, diabetes and related complications. The present invention further provides combinatorial cancer therapies, comprising the heparanase-neutralizing mAb and an additional anti-cancer treatment such as chemotherapy or radiation.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes

Abstract

Compounds represented by general Formulae I to IV as described herein are disclosed. Further disclosed are composition utilizing the herein disclosed compounds and using the same for the treatment of glycogen storage disorders.

IPC Classes  ?

• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 487/08 - Bridged systems

Abstract

Devices and method for determining a pupil size of a subject having closed eyelids.

IPC Classes  ?

• A61B 3/11 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for measuring interpupillary distance or diameter of pupils
• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• A61B 3/14 - Arrangements specially adapted for eye photography
• A61B 8/10 - Eye inspection
• A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
• A61B 90/50 - Supports for surgical instruments, e.g. articulated arms

Abstract

The present invention is directed to a pharmaceutical composition including any one of: (i) a S1c6a19 inhibitor; (ii) a S1c7a8 inhibitor; and (iii) a combination of (i) and (ii), and methods of using same, such as for inhibiting or reducing mTOR signaling in a brush border cell, and for treating or preventing fibrosis and/or kidney dysfunction in a subject in need thereof.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• C12N 15/09 - Recombinant DNA-technology

Abstract

Provided herein are methods, compositions of matter, and devices for treating diseases and illnesses of the eye, including retinal conditions such as macular degeneration.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A61L 27/38 - Animal cells
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention is directed to a method for treating an IFN-γ associated disease or disorder in a subject in need thereof, including administering to the subject a pharmaceutical composition including a therapeutically effective amount of a compound capable of manipulating or modulating PD -L1 signaling or pathway.

IPC Classes  ?

• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 35/00 - Antineoplastic agents
• C12N 5/07 - Animal cells or tissues

Abstract

The present invention relates to a device for repair of a region within an ear via a natural orifice, the device comprising a body. The body comprises a first port for visibly identifying the region to be sealed, the region being inside the ear; and a second port through which a seal can be introduced into the ear through the device. The region comprises a perforation of a tympanic membrane of the ear and the device is a speculum. The present invention also relates to method for repairing a perforation in a tympanic membrane using the same device.

IPC Classes  ?

• A61F 11/00 - Methods or devices for treatment of the ears or hearing sense Non-electric hearing aidsMethods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing senseProtective devices for the ears, carried on the body or in the hand
• A61B 1/227 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for ears, i.e. otoscopes
• A61F 2/18 - Internal ear or nose parts, e.g. ear-drums

Abstract

There are provided herein methods, devices, kits and systems utilizing respiratory mask for delivering pressurized fluid to a subject via inhalation in an efficient manner. The fluid may include gas and/or drug and by utilizing the methods, devices, kits and systems provided, efficient drug delivery to the subject's airways is achieved. The systems, devices, kits and methods further allow inducing insufflation/exsufflation in particular in subjects having impaired suffering from low neuromotor capacity, such as spinal cord injuries (SCI) patients.

IPC Classes  ?

• A61M 15/00 - Inhalators
• A61M 13/00 - Insufflators for therapeutic or disinfectant purposes
• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
• A61M 16/06 - Respiratory or anaesthetic masks

Abstract

The present invention provides biomarkers allowing the diagnosis of symptomatic congenital cytomegalovirus (CMV) infection and in particular to differentiate between symptomatic and asymptomatic infected fetuses, methods of diagnosis of CMV using said biomarkers, diagnostic kits comprising thereof, and use of the kits and methods of diagnosing fetuses infected with a symptomatic congenital cytomegalovirus (CMV).

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention provides biomarkers allowing the diagnosis of symptomatic congenital cytomegalovirus (CMV) infection and in particular to differentiate between symptomatic and asymptomatic infected fetuses, methods of diagnosis of CMV using said biomarkers, diagnostic kits comprising thereof, and use of the kits and methods of diagnosing fetuses infected with a symptomatic congenital cytomegalovirus (CMV).

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention provides a system comprising stimuli-responsive microcapsule- in-microcapsule multiple load carriers, uses thereof and processes for their preparation.

IPC Classes  ?

• B01J 13/04 - Making microcapsules or microballoons by physical processes, e.g. drying, spraying
• B01J 13/14 - Polymerisation, crosslinking
• B01J 13/22 - Coating
• A61K 9/50 - Microcapsules
• A61K 38/28 - Insulins
• A61K 38/44 - Oxidoreductases (1)
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides

Abstract

The present invention relates to compounds, compositions and methods for treating fibrosis. In particular, compounds that inhibit or downregulate Sirtuin 1 (SIRT1) activity, which are particularly useful in the treatment of Idiopathic Pulmonary Fibrosis (IPF) are provided.

IPC Classes  ?

• C07C 259/06 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
• C07D 487/04 - Ortho-condensed systems
• C07D 209/34 - Oxygen atoms in position 2
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/404 - Indoles, e.g. pindolol
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

Lactobacillus crispatusLactobacillus crispatus, thereby treating the bacterial vaginosis.

IPC Classes  ?

• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61P 31/04 - Antibacterial agents

Abstract

The present invention provides compositions having one or more agents capable of increasing expression of one or more endogenous tumor suppressive mi RNAs in one or more producing cells, such that the endogenous mi RNAs can affect one or more target cancer cells. Further provided are method and uses thereof for treating cancer.

IPC Classes  ?

• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61P 35/00 - Antineoplastic agents

Abstract

Methods of disrupting a biofilm and/or preventing formation of a biofilm are provided. Accordingly there is provided a method of reducing or preventing formation of a biofilm and/or disrupting a biofilm comprising contacting a biofilm-producing microorganism with a carbonic anhydrase inhibitor; a urease inhibitor; a Ca2+ ATPase inhibitor; a tlp activator; and/or a myo-inositol catabolism pathway activator. Also provided are articles of manufacture and methods of treating a medical condition in which disrupting a biofilm and/or preventing formation of same is beneficial and methods of predicting or increasing sensitivity to an anti-microbial agent.

IPC Classes  ?

• A61K 38/14 - Peptides containing saccharide radicalsDerivatives thereof
• A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising use of artemisone in combination with at least one antiviral compound selected from maribavir, cidofovir, brincidofovir, valganciclovir, and letermovir, and the combination provides a synergistic anti-viral effect. The invention also provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising the use of artemisone in combination with ganciclovir, wherein the molar ratio between artemisone and ganciclovir is about 1:100 to 100:1, and the combination provides a synergistic anti-viral effect. Pharmaceutical compositions comprising artemisone and at least one of said antiviral compounds are provided as well.

IPC Classes  ?

• A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
• A61P 31/12 - Antivirals
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom

Abstract

The invention relates to cancer management, specifically to therapeutic combinations and methods for immunotherapy of tumors and malignancies. More specifically, embodiments of the invention provide compositions, methods, pharmaceutical packages and combined preparations employing the use of a SLAMF6-mediated T cell activator in combination with a LAG3 inhibitor.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to nucleic acid agents modulating the expression of SLAMF6 isoforms, compositions comprising same and methods for their use in immunomodulation. Specifically, provided are splice-switching oligonucleotides and constructs useful in cancer immunotherapy.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to nucleic acid agents modulating the expression of SLAMF6 isoforms, compositions comprising same and methods for their use in immunomodulation. Specifically, provided are splice-switching oligonucleotides and constructs useful in cancer immunotherapy.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to cancer management, specifically to therapeutic combinations and methods for immunotherapy of tumors and malignancies. More specifically, embodiments of the invention provide compositions, methods, pharmaceutical packages and combined preparations employing the use of a SLAMF6-mediated T cell activator in combination with a LAG3 inhibitor.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure provides endoscopic retrograde cholangiopancreatography (ERCP) catheter systems having multiple ports and sensors configured to determine the location of the catheter's and/or guidewire's distal end as well as optional one or more magnetic bending aids, configured to aim a guidewire to the desired duct location. Further provided is a guidewire having a magnetic end and optional sensing elements. Also provided are methods of using the catheters and/or guidewires in ERCP procedures.

IPC Classes  ?

• A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61M 25/00 - CathetersHollow probes
• A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters

Abstract

A method of generating human mature oligodendrocytes is disclosed. The method comprises contacting a cell population which comprises human pre-oligodendrocytes with an inhibitor of the MAPK/ERK pathway under conditions that allow the pre-oligodendrocytes to differentiate into mature oligodendrocytes. Use of the MAPK/ERK pathway inhibitor for treating diseases is also disclosed.

IPC Classes  ?

• C12N 5/079 - Neural cells
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

A method of generating human mature oligodendrocytes is disclosed. The method comprises contacting a cell population which comprises human pre-oligodendrocytes with an inhibitor of the MAPK/ERK pathway under conditions that allow the pre-oligodendrocytes to differentiate into mature oligodendrocytes. Use of the MAPK/ERK pathway inhibitor for treating diseases is also disclosed.

IPC Classes  ?

• C12N 5/079 - Neural cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

A culture of human pluripotent stem cells (hPSCs) is disclosed. In the culture, more than 50 % of the hPSCs are formative hPSCs and are capable of renewing. Uses thereof are also disclosed.

IPC Classes  ?

• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/074 - Adult stem cells
• C12N 5/0797 - Stem cellsProgenitor cells

Abstract

A culture of human pluripotent stem cells (hPSCs) is disclosed. In the culture, more than 50 % of the hPSCs are formative hPSCs and are capable of renewing. Uses thereof are also disclosed.

IPC Classes  ?

• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/074 - Adult stem cells
• C12N 5/0797 - Stem cellsProgenitor cells

Abstract

A method of ascertaining the methylation status of a double-stranded, cell-free DNA molecule in a specimen is disclosed. The method comprises ascertaining the methylation status of at least two methylation sites of the same double-stranded cell-free DNA molecule, wherein said double-stranded, cell-free DNA molecule comprises a nucleotide sequence which comprises no more than 300 base pairs and is comprised in a sequence as set forth in any one of SEQ ID NOs: 2-117 or 121-177.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/686 - Polymerase chain reaction [PCR]